drugset / Trial / NCT05285839
Dupixent and Narrowband UVB for Atopic Dermatitis
Phase 4
Recruiting
40 enrolled
Psoriasis Treatment Center of Central New Jersey
Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Timeline
- Start
- 2022-04-19
- Primary completion
- 2024-12-01
- Completion
- 2024-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 300 mg | — |